Advertisement
Endo Pharmaceuticals
Subscribe to Endo Pharmaceuticals

The Lead

Endo and BioDelivery Sciences Announce Phase III Results for BEMA buprenorphine in Opioid-Experienced Patients with Chronic Pain

July 7, 2014 8:10 am | News | Comments

BEMA buprenorphine is being developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in both patients who are opioid naive and opioid experienced.

Endo to Acquire DAVA Pharmaceuticals

June 25, 2014 9:17 am | News | Comments

Endo International has reached a definitive agreement to acquire DAVA Pharmaceuticals, Inc., a...

Chicago Sues Over Painkiller Marketing

June 3, 2014 3:39 pm | by CARLA K. JOHNSON, AP Medical Writer | News | Comments

The lawsuit filed Monday in Cook County Circuit Court states the city has paid nearly $9.5...

Asana BioSciences, an Amneal Alliance Company, Acquires Branded Drug Discovery Platform from Endo International

June 3, 2014 8:12 am | News | Comments

Asana BioSciences, an independent member of the Amneal Alliance of Companies, has acquired the...

View Sample

FREE Email Newsletter

California Counties Sue Over Painkiller Marketing

May 22, 2014 3:18 pm | by PAUL ELIAS, Associated Press | News | Comments

Two California counties have filed a lawsuit accusing five drug companies of waging a campaign of deception to boost the sales of painkillers behind the nation's prescription drug addiction problem.         

Endo to Acquire Specialty Pharmaceuticals Company Somar

April 29, 2014 8:39 am | News | Comments

Endo International has entered into a definitive agreement under which Endo will acquire Grupo Farmaceutico Somar, a privately-owned specialty pharmaceuticals company based in Mexico City, Mexico, for cash consideration.     

Endo Appoints New Chief Scientific Officer and Global Head of R&D and Quality

March 7, 2014 8:04 am | News | Comments

Endo International has appointed Susan Hall, Ph.D. as executive vice president, chief scientific officer and global head of research & development and quality, effective March 10, 2014.           

Advertisement

FDA Approves Endo U.S. Testosterone Replacement Therapy

March 6, 2014 8:13 am | News | Comments

Endo Pharmaceuticals has received FDA approval of AVEED (testosterone undecanoate) injection for the treatment of adult men with hypogonadism (commonly known as Low-T) that is associated with a deficiency or absence of the male hormone testosterone.

Endo Shareholders Approve Acquisition of Paladin Labs

February 26, 2014 3:51 pm | News | Comments

Endo Health Solutions Inc. has announced that, at the shareholder meeting held today, proposals related to Endo's proposed acquisition of Paladin Labs Inc. were approved by Endo's shareholders.         

Endo Health to Pay $192.7M in Government Settlement

February 21, 2014 3:36 pm | by The Associated Press | News | Comments

Endo Health will pay almost $193 million to resolve claims that it improperly marketed the shingles treatment Lidoderm for unapproved uses like treating lower back pain.              

Endo Completes Acquisition of Specialty Generics Company Boca Pharmacal

February 3, 2014 8:09 am | News | Comments

Endo Health Solutions today announced that its Qualitest subsidiary has completed the acquisition of privately held Boca Pharmacal, a specialty pharmaceutical company, for approximately $225 million in cash.       

Endo Health Sells HealthTronics for up to $130M

January 9, 2014 1:29 pm | News | Comments

Endo Health Solutions said Thursday it will sell its HealthTronics urology unit for up to $130 million as it streamlines its business. Investment firm Altaris Capital Partners will pay $85 million upfront for HealthTronics, and Endo could get an additional $45 million based on the performance of the business.

Advertisement

Endo to Acquire Specialty Pharmaceutical Company NuPathe

December 16, 2013 8:27 am | News | Comments

Endo Health Solutions will acquire NuPathe Inc. for $2.85 per share in cash, or approximately $105 million.  In addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe's migraine treatment ZECUITY are achieved over time.

Endo Health to Buy Paladin Labs for $1.5B

November 5, 2013 8:07 am | News | Comments

Endo Health is buying the Canadian specialty drug maker Paladin Labs for about $1.5 billion, and both will then be folded into a newly-formed Irish holding company.             

Endo Health Names Upadhyay as its Next CFO

September 9, 2013 2:59 pm | by The Associated Press | News | Comments

Endo Health Solutions said Monday that former Becton Dickinson executive Suketu Upadhyay will join the company as chief financial officer Sept. 23. Upadhyay has been Becton Dickinson & Co.'s chief accounting officer and was interim CFO from November 2012 to July 2013.

Endo Health Says FDA Accepts Aveed Application

September 5, 2013 10:56 am | by The Associated Press | News | Comments

Endo Health Solutions said Thursday that regulators accepted for review new data for its long-acting testosterone injection Aveed and will make a ruling on the drug by Feb. 28. The Food and Drug Administration asked Endo for more information in May. Endo said the FDA was concerned about risks and...

Endo to Acquire Boca Pharmacal for $225M

August 28, 2013 9:16 am | News | Comments

Endo Health Solutions announced that its Qualitest subsidiary has reached a definitive agreement to acquire privately held Boca Pharmacal, a specialty generics company, for $225 million in cash.  The transaction is expected to enhance the growth platform and pipeline for Endo's Qualitest business and is consistent with Endo's strategic transformation into a leading specialty healthcare company. 

Advertisement

Endo Second Quarter Net Income Rises as Charges Decrease

August 6, 2013 3:11 pm | by The Associated Press | News | Comments

Endo Health Solutions Inc. said Tuesday its net income rose in the second quarter despite a series of charges related to its planned shift in business strategy and an allowance for potential lawsuits. The company also raised its full-year guidance, but shares slipped in afternoon trading In June...

Endo to Explore Options on Two Business Units, Cut Jobs

June 5, 2013 6:39 pm | by The Associated Press | News | Comments

Endo Health Solutions Inc. on Wednesday partially reversed course on several years of expansion, saying it will explore strategic options for two businesses and eliminate almost 700 jobs. The company said it will consider options for its HealthTronics urology business and for its branded drug...

Endo Says FDA Wants More Information on Aveed

May 30, 2013 5:33 pm | by The Associated Press | News | Comments

Endo Health Solutions Inc. said Thursday the Food and Drug Administration wants more information about its long-acting testosterone injection Aveed before it will approve the drug. Endo said the FDA is concerned about risks and severe complications related to post-injection reactions. Endo said...

Endo Health CFO, COO Leaving the Company

May 29, 2013 10:40 am | by The Associated Press | News | Comments

Endo Health Solutions Inc. said Wednesday that Chief Financial Officer Alan G. Levin and Chief Operating Officer Julie H. McHugh are both leaving the company. The drug developer said that Levin will remain as CFO until the fall. McHugh's resignation is effective immediately. Endo said it created...

FDA Denies Request to Block Generic Painkiller

May 10, 2013 5:53 pm | by The Associated Press | News | Comments

In a surprise move Friday, federal health regulators denied a request by Endo Health Solutions to block generic versions of its painkiller Opana ER, which the company argued are more easily abused than its branded product. Endo's Opana ER is a long-acting narcotic drug used to treat moderate and...

Endo Health Turns First Quarter Profit, Affirms 2013 Forecast

May 7, 2013 8:46 am | by The Associated Press | News | Comments

Endo Health Solutions Inc. turned a first-quarter profit, reversing a lost at the start of 2012, when the drug developer absorbed a sizeable pre-tax charge tied to a settlement and license agreement. The Malvern, Pa., company said Tuesday it earned $15.3 million, or 14 cents per share, in the...

FDA Panel Split on Safety of Testosterone Drug

April 18, 2013 4:46 pm | by MATTHEW PERRONE - AP Health Writer - Associated Press | News | Comments

Federal health experts issued a split opinion Thursday on whether a long-acting testosterone injection from Endo Health Solutions is safe. A Food and Drug Administration panel voted 9-9 on the safety of Endo's Aveed, a drug designed to be injected once every 10 weeks to boost testosterone in men...

Watson's Generic Lidoderm Receives FDA Approval

August 24, 2012 3:57 am | News | Comments

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has received final approval from the FDA on its Abbreviated New Drug Application (ANDA) for lidocaine topical patch 5%, the generic equivalent to Endo's Lidoderm.

Watson Announces Lidoderm Patent Challenge Settlement

May 29, 2012 4:01 am | News | Comments

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an agreement with Endo Pharmaceuticals Inc. and Teikoku Seiyaku Co., Ltd to settle all outstanding patent litigation related to Watson's generic version of Lidoderm.

Endo Pharma Sees Earnings Loss After $100 Million Charge

May 2, 2012 5:10 am | by The Associated Press | News | Comments

Endo Pharmaceuticals turned a first-quarter loss after absorbing a $110-million pre-tax charge connected to a settlement and license agreement with Impax Laboratories Inc.Endo, based in Chadds Ford, Pa., said Tuesday it lost $87.3 million, or 75 cents per share, in the three months that ended...

Endo Pharma Signs Licensing Deal with BioDelivery

January 6, 2012 3:20 am | News | Comments

CHADDS FORD, Pa. (AP) — Endo Pharmaceuticals Inc. said today it has agreed to pay up to $180 million for licensing rights to market a potential pain treatment from BioDelivery Sciences International Inc. that would be delivered through a dissolvable film applied to the inside of the cheek.

Endo Announces FDA Approval of a New Formulation of Opana ER Designed To Be Crush-Resistant

December 12, 2011 3:12 am | News | Comments

Endo Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of Opana ER designed to be crush-resistant.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading